Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645201 | 0.81 | HSPB1 (0.45) | PIN1HSPB1MAPTSLC22A12MEN1 | |
| SCHEMBL15820839 | 0.79 | HSPB1 (0.59) | PIN1HSPB1MAPTMEN1KMT2A | |
| SCHEMBL2643872 | 0.79 | PIN1 (0.43) | PIN1HSPB1MAPTSLC22A12POLB | |
| SCHEMBL9132057 | 0.78 | HPGD (0.58) | PIN1HSPB1MEN1KMT2AF2 | |
| SCHEMBL458453 | 0.73 | VCAM1 (0.44) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL2644525 | 0.73 | PIN1 (0.48) | PIN1MAPTSLC22A12POLBGAA | |
| SCHEMBL7025384 | 0.72 | SLC22A12 (0.41) | PIN1SLC22A12EZH2POLBGAA | |
| SCHEMBL27546530 | 0.71 | SLC22A12 (0.45) | MAPTSLC22A12EZH2POLBGAA | |
| SCHEMBL2313882 | 0.70 | HTT (0.49) | MAPTMEN1KMT2AL3MBTL1POLB | |
| SCHEMBL4374421 | 0.70 | AR (0.55) | HSPB1SLC22A12EZH2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | PIN1 4516/4885HSPB1 3024/4885MAPT 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.